Last Updated: November 16, 2026

Details for Patent: 10,052,267

« Back to Dashboard


Which drugs does patent 10,052,267 protect, and when does it expire?

Patent 10,052,267 protects QBREXZA and is included in one NDA.

This patent has nine patent family members in six countries.

Summary for Patent: 10,052,267
Title:Topical glycopyrrolate formulations
Abstract:Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer.
Inventor(s):Michael Johnston, Robert James Houlden
Assignee: Rose U LLC
Application Number:US15/662,166
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,052,267
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;
Patent landscape, scope, and claims:

US Patent 10,052,267: Glycopyrrolate Solution, Hyperhidrosis Wipe, and Patent Landscape

US Patent 10,052,267 protects a topical glycopyrrolate formulation built around four technical elements: glycopyrrolate salt, a defined ethanol-water solvent system, a citric-acid buffer, and a mildly acidic pH. Dependent claims narrow the formulation to glycopyrrolate hydrobromide or glycopyrrolate p-toluenesulfonate, approximately 2% or 4% drug concentration, approximately 60:40 ethanol-water, and pH near 4.5. Separate claims cover an individually packaged wipe and topical treatment of hyperhidrosis. The claim structure is closely aligned with commercial glycopyrronium cloth products, including Qbrexza.

What does US Patent 10,052,267 protect?

The patent has three claim categories:

Claim category Claims Protected subject matter
Liquid composition 1-15 Glycopyrrolate solution with defined concentration, solvent ratio, buffer, pH and optional excipients
Packaged wipe 16-18 Hyperhidrosis wipe loaded with the claimed solution and sealed in a leakage-resistant pouch
Treatment method 19-20 Topical administration of the solution or wipe to reduce hyperhidrosis

The independent composition claim is claim 1. It requires every limitation listed below:

  1. A glycopyrrolate compound at approximately 0.5% to 4.0% w/w.
  2. Ethanol and water at approximately a 50:50 to 60:40 weight ratio.
  3. A buffer containing an acid and a base.
  4. Total buffer concentration of approximately 0.2% to 0.5% w/w.
  5. A pH of approximately 3.5 to 6 at 25°C.
  6. Citric acid as the acid.
  7. Sodium citrate or tromethamine as the base.
  8. A glycopyrrolate counterion derived from one of the listed inorganic or organic acids.

A competing product that omits one required limitation may avoid literal infringement of claim 1, although dependent claims, equivalents, manufacturing claims, or other patent families could remain relevant.

How should claim 1 be construed?

Claim 1 is a narrow formulation claim rather than a broad claim to topical glycopyrrolate generally. The central limitation is the combination of composition parameters. The patent does not claim every glycopyrrolate formulation, every topical anticholinergic product, or every treatment of hyperhidrosis.

Active pharmaceutical ingredient

The claim covers a glycopyrrolate compound in salt form. The listed counterions include:

  • Hydrochloride
  • Hydrobromide
  • Hydrofluoride
  • Hydroiodide
  • Sulfate
  • Nitrate
  • Phosphate
  • Acetate
  • Propionate
  • Glycolate
  • Pyruvate
  • Oxalate
  • Malate
  • Malonate
  • Succinate
  • Maleate
  • Fumarate
  • Tartrate
  • Citrate
  • Benzoate
  • Cinnamate
  • Mandelate
  • Methanesulfonate
  • Ethanesulfonate
  • p-Toluenesulfonate
  • Salicylate

Claims 7 and 8 specifically select the hydrobromide and p-toluenesulfonate salts. These dependent claims are commercially significant because glycopyrronium tosylate, also known as glycopyrrolate p-toluenesulfonate, is the active salt used in Qbrexza.

The claim language appears directed to a salt of glycopyrrolate rather than only the free base. Salt selection can affect solubility, stability, crystallinity, manufacturing, and skin delivery.

Ethanol-water solvent system

Claim 1 covers an ethanol-water ratio from approximately 50:50 to 60:40 by weight. Claim 5 narrows the ratio to approximately 60:40. Claim 6 narrows the ethanol concentration to approximately 53.7% to 57.3% w/w, with water making up the balance.

This limitation is important because it gives the claim a measurable formulation boundary. A formulation containing approximately 55% ethanol and 45% water would fall within claim 6, assuming the remaining claim limitations are met. A formulation using a materially different solvent system, such as predominantly water, is outside the literal scope of these limitations.

The ratio is measured by weight, not volume. That distinction matters in product testing and infringement analysis.

Buffer and pH limitations

The buffer must contain citric acid and either sodium citrate or tromethamine. The total acid-plus-base concentration must be approximately 0.2% to 0.5% w/w. The pH must be approximately 3.5 to 6 at 25°C.

Claims 2 and 3 narrow the pH to approximately 4 to 5 and approximately 4.5, respectively. These claims create a strong product-specific position where a commercial formulation uses citric acid, sodium citrate or tromethamine, and a pH centered near 4.5.

The phrase "at an acid:base ratio sufficient to maintain" the specified pH makes the exact ratio functionally dependent on the formulation. The claim does not provide one fixed acid-to-base numerical ratio. Laboratory testing would likely examine the actual acid and base concentrations, final pH, temperature, and analytical method.

What are the dependent claims worth commercially?

The dependent claims provide fallback positions if the broad composition claim is challenged or narrowed.

Claim Limitation Commercial relevance
2 pH approximately 4 to 5 Captures a commercially practical acidic range
3 pH approximately 4.5 Potentially tracks a commercial product specification
4 Less than 1% degradation over specified storage periods Adds a stability-performance limitation
5 Ethanol-water ratio approximately 60:40 Narrows solvent composition
6 Ethanol approximately 53.7% to 57.3% w/w Creates a precise formulation range
7 Glycopyrrolate hydrobromide Covers a selected salt
8 Glycopyrrolate p-toluenesulfonate Covers glycopyrronium tosylate
9 Glycopyrrolate approximately 2.0% w/w Relevant to commercial-strength products
10 Glycopyrrolate approximately 4.0% w/w Covers a higher-strength formulation
11 Tromethamine buffer base Alternative buffer implementation
12 Sodium citrate buffer base Alternative buffer implementation
13 Propylene glycol Adds a cosolvent or humectant option
14-15 Hydrophobic-hydrophilic polymer system Covers film-forming or delivery-enhancing systems

Claim 4 is materially different from the concentration and pH claims. It requires a degradation result of less than 1% during storage at 0°C to 25°C for at least one of several periods. This may require stability testing rather than simple inspection of a product label.

Claims 14 and 15 expand the formulation concept to polymer-containing products. Claim 15 identifies polyvinylpyrrolidone and a butyl ester of polyvinylmethylether/maleic anhydride copolymer. These limitations may be relevant to adhesion, residence time, film formation, or controlled deposition on skin.

What formulations are protected by US 10,052,267?

A formulation is a strong literal candidate for claim coverage if it has the following profile:

Parameter Representative claimed range
Glycopyrrolate salt 0.5% to 4.0% w/w
Ethanol 50% to 60% of the ethanol-water system
Water 40% to 50% of the ethanol-water system
Buffer acid Citric acid
Buffer base Sodium citrate or tromethamine
Total buffer 0.2% to 0.5% w/w
pH 3.5 to 6 at 25°C
Preferred pH Approximately 4.5
Preferred salt Glycopyrrolate hydrobromide or p-toluenesulfonate
Optional excipients Propylene glycol or specified polymer system

The claim does not require the formulation to be packaged in a wipe unless claims 16-18 are asserted. A bottle, vial, pump, applicator, or other container could potentially satisfy claims 1-15 if its formulation meets the required limitations.

What does the patent protect about wipes?

Claims 16-18 cover an individually packaged wipe for treating hyperhidrosis. The wipe must be loaded with the claimed glycopyrrolate solution and contained in a pouch resistant to leakage.

Claim 17 covers a broad range of wipe substrates:

  • Nonwoven material
  • Paper
  • Woven material
  • Knitted material
  • Tufted material
  • Stitched-bonded material
  • Wet-milled felted material

Claim 18 narrows the pouch to one with an inner lining of linear low-density polyethylene, or LLDPE.

The wipe claims therefore combine a formulation limitation with a packaging and delivery format. A wipe using glycopyrrolate in a materially different formulation may avoid these claims even if it treats the same condition. Conversely, a product using the claimed formulation in a pouch may face risk even if the substrate differs from the commercial reference product, because claim 17 covers multiple substrate classes.

What are the method-of-use claims?

Claims 19 and 20 cover topical treatment of hyperhidrosis in a mammal.

Claim 19 covers topical administration of the solution. Claim 20 covers topical administration of the wipe after removal from its pouch.

The method claims require:

  1. A mammalian subject.
  2. Topical administration.
  3. Administration to an area of the body.
  4. Reduction of hyperhidrosis.
  5. Use of the claimed solution or wipe.

The method claims are narrower than a generic claim to treating sweating because they incorporate the composition or wipe limitations through dependency. A product label that directs users to apply the claimed formulation to hyperhidrotic areas may be relevant to induced or contributory infringement theories, depending on the product’s composition and commercial instructions.

When does US Patent 10,052,267 lose exclusivity?

US Patent 10,052,267 issued on August 21, 2018. Its enforceable term is determined by the earliest effective US nonprovisional filing date in the priority chain, adjusted for patent term adjustment and subject to any terminal disclaimer. A provisional filing date does not normally establish the patent-term start date.

The patent number and claim text alone do not establish a legally reliable expiration date. The controlling records are the patent’s front page, continuity data, Patent Center transaction history, patent-term adjustment calculation, and any terminal disclaimer filed with the USPTO.[1]

The patent’s practical exclusivity also depends on:

  • Whether it is listed in the FDA Orange Book.
  • Whether the listed claims correspond to an approved drug product.
  • Whether the patent has been disclaimed, reissued, or amended.
  • Whether a generic applicant files an ANDA with a Paragraph IV certification.
  • Whether a court invalidates, narrows, or finds the asserted claims not infringed.

What is the FDA and Orange Book status of the relevant product?

Qbrexza, a glycopyrronium cloth, was approved by the FDA for primary axillary hyperhidrosis in patients 9 years of age and older. The product contains glycopyrronium tosylate and is administered as a single-use topical cloth.[2]

The FDA-approved product is commercially relevant to this patent because the claimed architecture includes:

  • Glycopyrrolate p-toluenesulfonate.
  • Approximately 2% glycopyrrolate compound.
  • An ethanol-water topical solution.
  • Citric-acid buffering.
  • Individually packaged wipe delivery.

The FDA Orange Book is the controlling source for current patent listings and regulatory exclusivity. Orange Book entries may change through delisting, patent expiry, submission of new patent information, or FDA administrative action.[3] Patent 10,052,267 should therefore be evaluated together with every other patent listed for the applicable Qbrexza NDA, rather than treated as the complete product estate.

FDA exclusivity and patent exclusivity are separate. A drug may have no remaining regulatory exclusivity but still face listed patent barriers. Conversely, patent expiry does not itself eliminate other requirements for ANDA approval.

What Paragraph IV challenges and generic-entry risks exist?

A generic applicant seeking approval for a glycopyrronium topical product could pursue several strategies:

Strategy Potential effect
Paragraph III certification Accepts listed patent expiry and delays approval
Paragraph IV certification Challenges validity, enforceability, or infringement
Formulation redesign Changes salt, buffer, solvent ratio, pH or concentration
Different dosage form Uses a solution, pump, gel or other format instead of a wipe
Different indication Avoids or narrows method-of-use exposure
Label carve-out Removes a patented use where FDA rules permit
505(b)(2) pathway May be relevant for a modified formulation or delivery system

The principal technical design-around routes are changing at least one required limitation:

  • Replace ethanol-water with another solvent system.
  • Use a pH outside the claimed range.
  • Use a buffer other than citric acid plus sodium citrate or tromethamine.
  • Use a different glycopyrrolate salt.
  • Use a concentration below 0.5% or above 4.0%.
  • Deliver the drug through a non-wipe format.
  • Use a different treatment indication or labeling strategy.

These routes are not automatically safe. A modified product could still implicate other patents, doctrine-of-equivalents arguments, or noninfringement disputes over overlapping ranges.

Which companies are relevant to the patent landscape?

The commercial landscape includes several company groups:

Company or group Relevance
Dermira Original developer associated with Qbrexza and the glycopyrronium topical platform
Almirall Acquired Dermira and obtained Qbrexza-related commercial assets
Generic pharmaceutical companies Potential ANDA applicants and Paragraph IV challengers
Contract manufacturers May control formulation, cloth loading, pouch sealing or process know-how
Dermatology companies Potential licensors, acquirers or competing developers

Almirall completed its acquisition of Dermira in 2020, making Almirall the principal commercial successor for Qbrexza-related assets.[4] The patent itself is only one part of the intellectual-property position. Know-how concerning cloth saturation, pouch barrier performance, uniform dosing, stability, and manufacturing yield may create practical barriers even after patent expiry.

How strong is the patent estate?

The patent has meaningful strength against products that copy the commercial formulation architecture. Its strongest features are:

  • A defined combination of drug, solvent, buffer, and pH.
  • Specific dependent claims directed to glycopyrrolate p-toluenesulfonate.
  • A 2% concentration claim that may track commercial strength.
  • A wipe claim tied to the formulation.
  • A method claim tied to topical hyperhidrosis treatment.
  • Stability and polymer-system fallback claims.

Potential vulnerabilities include:

  • Narrow numerical ranges.
  • Possible prior-art disclosures of topical glycopyrrolate solutions.
  • The need to prove every formulation limitation.
  • The functional degradation limitation in claim 4.
  • Potential written-description or enablement disputes across numerous salt, solvent and buffer combinations.
  • Design-around opportunities using different salts, buffers, pH values or delivery systems.

The estate is stronger against a close copy than against a redesigned generic formulation. A generic manufacturer can target the formulation limitations rather than challenge every claim directly.

Does biosimilar risk apply?

No. Glycopyrrolate is a small-molecule active ingredient, not a biologic. Biosimilar approval under the Public Health Service Act is not the relevant pathway. The principal competitive threat is an ANDA generic or, for a materially modified product, a 505(b)(2) application.

What litigation and settlement issues should be reviewed?

A complete litigation assessment requires the federal docket, USPTO records and FDA Orange Book history. The relevant questions are:

  • Has an ANDA applicant filed a Paragraph IV certification?
  • Was a 30-month stay triggered under the Hatch-Waxman Act?
  • Were claims 1, 3, 8, 9, 16 or 20 asserted?
  • Was the case dismissed, settled, or adjudicated?
  • Did a settlement permit an agreed generic launch date?
  • Did the parties exchange a covenant not to sue?
  • Were patent claims amended or disclaimed?
  • Were manufacturing or supply rights licensed?

Settlement terms in pharmaceutical patent cases may include launch dates, licenses, authorized-generic commitments, supply agreements and restrictions on challenge rights. These terms can materially alter the practical entry date even when the patent’s nominal expiration date remains unchanged.

What is the competitive position versus other hyperhidrosis treatments?

Qbrexza competes with aluminum chloride products, iontophoresis, botulinum toxin injections, oral anticholinergics and other topical therapies. Its principal differentiation is topical anticholinergic delivery through a pre-moistened cloth.

The patent’s coverage is most relevant to competitors attempting to reproduce that combination of:

  • Pre-measured topical dosing.
  • Glycopyrronium tosylate.
  • Ethanol-water vehicle.
  • Citric-acid buffer.
  • Individually packaged wipe.
  • Hyperhidrosis-specific labeling.

Products using aluminum chloride, oxybutynin, botulinum toxin, or a non-glycopyrrolate active ingredient generally fall outside this patent’s composition claims, although they may be subject to separate patents.

Key Takeaways

  • US Patent 10,052,267 is primarily a formulation patent with related wipe and treatment-method claims.
  • Claim 1 requires a specific glycopyrrolate salt formulation, ethanol-water ratio, citric-acid buffer, buffer concentration and pH.
  • Claims 3, 6, 8 and 9 are particularly relevant to a commercial product using approximately 2% glycopyrrolate p-toluenesulfonate at approximately pH 4.5.
  • Claims 16-18 extend protection to individually packaged wipes and LLDPE-lined pouches.
  • Claims 19-20 cover topical hyperhidrosis treatment using the claimed solution or wipe.
  • The patent does not cover every topical glycopyrrolate product.
  • Generic design-around opportunities include changing the salt, solvent, buffer, pH, concentration or delivery format.
  • Qbrexza is the principal commercial product associated with the claimed formulation architecture.
  • The patent’s exact expiration date must be taken from the USPTO term and continuity records, not inferred from the grant date.
  • Glycopyrrolate is a small molecule, so generic ANDA and Paragraph IV risk, not biosimilar risk, is the relevant competitive framework.

FAQs About US Patent 10,052,267

Does US 10,052,267 cover glycopyrronium tosylate?

Yes. Claim 8 expressly covers a glycopyrrolate compound whose counterion is prepared from p-toluenesulfonic acid, corresponding to glycopyrrolate p-toluenesulfonate or glycopyrronium tosylate, when the other claim 1 limitations are met.

Does the patent cover a glycopyrrolate cream?

Not necessarily. A cream would need to satisfy the composition limitations, including the ethanol-water ratio, citric-acid buffer, pH and glycopyrrolate concentration. A conventional emulsion cream would not automatically fall within the claims.

Can a generic avoid the patent by using glycopyrrolate hydrobromide?

Potentially, but not automatically. Hydrobromide is expressly covered by claim 7 when the formulation also meets the requirements inherited from claim 1.

Is a product at pH 6.1 outside claim 1?

Likely outside the literal pH range of claim 1, which ends at approximately pH 6.0. The legal result would depend on the measured pH, the meaning of "about," and any asserted equivalents theory.

Does a different wipe material avoid claims 16 and 17?

Not necessarily. Claim 17 covers multiple substrate categories, including nonwoven, paper, woven, knitted and other materials. A different substrate may still fall within the claim if it is loaded with the claimed solution and used in the claimed packaged wipe.

Is the patent relevant to oral glycopyrrolate products?

The patent is directed to topical solutions, wipes and topical treatment of hyperhidrosis. An oral glycopyrrolate product would generally not satisfy the topical composition, wipe or topical-administration limitations.

Sources

  1. United States Patent and Trademark Office. (2018). U.S. Patent No. 10,052,267, Glycopyrrolate formulations and methods of use thereof.
  2. U.S. Food and Drug Administration. (2018). Qbrexza prescribing information.
  3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  4. Almirall, S.A. (2020). Completion of acquisition of Dermira, Inc. and related Qbrexza commercial rights.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,052,267

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Journey QBREXZA glycopyrronium tosylate CLOTH;TOPICAL 210361-001 Jun 28, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,052,267

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008314628 ⤷  Start Trial
Australia 2014203072 ⤷  Start Trial
Canada 2702830 ⤷  Start Trial
European Patent Office 2200550 ⤷  Start Trial
European Patent Office 3415127 ⤷  Start Trial
Spain 2671874 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.